Shares of Nektar Therapeutics (NASDAQ:NKTR) traded up 5.2% during trading on Thursday . The stock traded as high as $40.88 and last traded at $40.69. 2,248,976 shares were traded during trading, a decline of 28% from the average session volume of 3,124,249 shares. The stock had previously closed at $38.68.
Several analysts have commented on the stock. ValuEngine cut shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday. BidaskClub cut shares of Nektar Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 24th. Zacks Investment Research upgraded shares of Nektar Therapeutics from a “hold” rating to a “buy” rating and set a $54.00 price objective for the company in a research note on Monday, July 16th. HC Wainwright set a $54.00 target price on shares of Nektar Therapeutics and gave the company a “hold” rating in a report on Friday, August 10th. Finally, TheStreet raised shares of Nektar Therapeutics from a “d” rating to a “c” rating in a report on Wednesday, August 8th. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the stock. Nektar Therapeutics currently has an average rating of “Buy” and an average target price of $82.91.
The company has a current ratio of 19.67, a quick ratio of 19.55 and a debt-to-equity ratio of 0.13. The firm has a market cap of $6.73 billion, a price-to-earnings ratio of -71.00 and a beta of 2.91.
Nektar Therapeutics (NASDAQ:NKTR) last posted its earnings results on Wednesday, August 8th. The biopharmaceutical company reported $5.33 earnings per share for the quarter, beating the consensus estimate of $5.22 by $0.11. The firm had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.03 billion. Nektar Therapeutics had a net margin of 65.69% and a return on equity of 174.70%. The business’s quarterly revenue was up 3043.7% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.39) EPS. As a group, analysts predict that Nektar Therapeutics will post 3.57 EPS for the current year.
In related news, Director R Scott Greer sold 10,000 shares of the business’s stock in a transaction on Tuesday, September 4th. The shares were sold at an average price of $67.39, for a total value of $673,900.00. Following the completion of the sale, the director now owns 140,333 shares of the company’s stock, valued at approximately $9,457,040.87. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Jeffrey Robert Ajer sold 6,750 shares of the business’s stock in a transaction on Thursday, September 20th. The stock was sold at an average price of $56.76, for a total transaction of $383,130.00. Following the completion of the sale, the director now directly owns 15,750 shares of the company’s stock, valued at approximately $893,970. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 96,000 shares of company stock valued at $5,825,680. Insiders own 4.31% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of NKTR. Dimensional Fund Advisors LP increased its holdings in Nektar Therapeutics by 50.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 208,021 shares of the biopharmaceutical company’s stock worth $22,104,000 after acquiring an additional 69,557 shares in the last quarter. LPL Financial LLC purchased a new stake in Nektar Therapeutics in the 1st quarter worth $359,000. Royal Bank of Canada increased its holdings in Nektar Therapeutics by 4,106.2% in the 1st quarter. Royal Bank of Canada now owns 99,728 shares of the biopharmaceutical company’s stock worth $10,597,000 after acquiring an additional 97,357 shares in the last quarter. Allianz Asset Management GmbH increased its holdings in Nektar Therapeutics by 12.1% in the 1st quarter. Allianz Asset Management GmbH now owns 103,684 shares of the biopharmaceutical company’s stock worth $11,018,000 after acquiring an additional 11,213 shares in the last quarter. Finally, Suntrust Banks Inc. purchased a new stake in Nektar Therapeutics in the 1st quarter worth $264,000. 91.94% of the stock is owned by institutional investors.
About Nektar Therapeutics (NASDAQ:NKTR)
Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.
See Also: What does the Dow Jones Industrial Average (DJIA) measure?
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.